Literature DB >> 27023912

Glycosylation is crucial for a proper catalytic site organization in human glucocerebrosidase.

Laercio Pol-Fachin1,2, Marina Siebert3,4, Hugo Verli3, Maria Luiza Saraiva-Pereira3,4,5.   

Abstract

Gaucher disease, an autosomal recessive disorder, is caused by a deficiency of glucocerebrosidase (GCase) enzyme, a peripheral membrane-associated glycoprotein that hydrolyses glucosylceramide in lysosomes. Glycosylation is essential for the development of a catalytically active enzyme, specifically in the first site, located at Asn19. However, both the molecular basis of the relevance of N-glycosylation over GCase activity and the effects of glycosylation over its structure and dynamics are still not fully understood. Thus, the present work evaluated GCase enzyme in increasing glycosylation content using triplicate unbiased molecular dynamics simulations. Accordingly, the N-linked glycan chains caused local conformational stabilization effects over the protein, as well as in regions flanking the enzyme catalytic dyad. In the case of the Asn19-linked glycan, it also occurred around region 438-444, where one of the most prevalent GCase mutations is found. Markedly, an increasing catalytic dyad organization was related to increasing glycosylation contents, offering the first atomic-level explanation for the experimental observation that GCase activity is controlled by glycosylation, especially at Asn19.

Entities:  

Keywords:  Enzyme; Gaucher disease; Glycan; Lysosome; Molecular dynamics

Mesh:

Substances:

Year:  2016        PMID: 27023912     DOI: 10.1007/s10719-016-9661-7

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  50 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

2.  Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.

Authors:  Susan D Orwig; Yun Lei Tan; Neil P Grimster; Zhanqian Yu; Evan T Powers; Jeffery W Kelly; Raquel L Lieberman
Journal:  Biochemistry       Date:  2011-11-14       Impact factor: 3.162

3.  Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.

Authors:  Raquel L Lieberman; Brandon A Wustman; Pedro Huertas; Allan C Powe; Corey W Pine; Richie Khanna; Michael G Schlossmacher; Dagmar Ringe; Gregory A Petsko
Journal:  Nat Chem Biol       Date:  2006-12-24       Impact factor: 15.040

4.  Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations.

Authors:  Benjamin Liou; Andrzej Kazimierczuk; Min Zhang; C Ronald Scott; Rashmi S Hegde; Gregory A Grabowski
Journal:  J Biol Chem       Date:  2005-11-17       Impact factor: 5.157

5.  Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase.

Authors:  S Van Weely; J M Aerts; M B Van Leeuwen; J C Heikoop; W E Donker-Koopman; J A Barranger; J M Tager; A W Schram
Journal:  Eur J Biochem       Date:  1990-08-17

Review 6.  Gaucher disease and other storage disorders.

Authors:  Gregory A Grabowski
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

7.  Solution conformation and dynamics of exopolysaccharides from Burkholderia species.

Authors:  Laercio Pol-Fachin; Rodrigo V Serrato; Hugo Verli
Journal:  Carbohydr Res       Date:  2010-06-25       Impact factor: 2.104

Review 8.  Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).

Authors:  Kathleen S Hruska; Mary E LaMarca; C Ronald Scott; Ellen Sidransky
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

9.  THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE.

Authors:  R O BRADY; J KANFER; D SHAPIRO
Journal:  J Biol Chem       Date:  1965-01       Impact factor: 5.157

10.  Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems.

Authors:  Yoram Tekoah; Salit Tzaban; Tali Kizhner; Mariana Hainrichson; Anna Gantman; Myriam Golembo; David Aviezer; Yoseph Shaaltiel
Journal:  Biosci Rep       Date:  2013-09-25       Impact factor: 3.840

View more
  3 in total

Review 1.  X-Ray Crystallography in Structure-Function Characterization of Therapeutic Enzymes.

Authors:  Anastassios C Papageorgiou
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 2.  Clinical Sphingolipids Pathway in Parkinson's Disease: From GCase to Integrated-Biomarker Discovery.

Authors:  Ali Esfandiary; David Isaac Finkelstein; Nicolas Hans Voelcker; David Rudd
Journal:  Cells       Date:  2022-04-15       Impact factor: 7.666

Review 3.  Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease.

Authors:  Laura J Smith; Chiao-Yin Lee; Elisa Menozzi; Anthony H V Schapira
Journal:  Front Neurol       Date:  2022-08-12       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.